We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Techlab

TECHLAB, Inc. develops, manufactures, and distributes rapid non-invasive intestinal diagnostics in the areas of intes... read more Featured Products: More products

Download Mobile App




Innovative C. Difficile Diagnostic Test Provides Both GDH and Toxin Results within 30 Minutes

By LabMedica International staff writers
Posted on 16 Jul 2024
Print article
Image: The C. DIFF QUIK CHEK COMPLETE test has received the first European IVDR Certification for combined GDH plus Toxin A/B test (Photo courtesy of TECHLAB)
Image: The C. DIFF QUIK CHEK COMPLETE test has received the first European IVDR Certification for combined GDH plus Toxin A/B test (Photo courtesy of TECHLAB)

Clostridium difficile is a leading cause of hospital-acquired diarrhea and pseudomembranous colitis. Infections typically occur when antibiotics disrupt the normal gut flora. Toxigenic strains of C. difficile produce toxins A and B, which are responsible for the symptoms of the infection. Diagnosing C. difficile can be complex because it is possible to carry the bacteria without it producing disease-causing toxins. All strains of C. difficile produce glutamate dehydrogenase (GDH), making GDH testing a useful initial screen for the infection. However, additional tests are necessary since a GDH-positive result does not confirm if the strain is toxin-producing, which is necessary to determine if the patient has an active infection or is just a carrier. Now, a new test that provides results for both GDH and the toxins within approximately 30 minutes can help healthcare professionals accurately distinguish between active infection and colonization in a cost-effective and clinically relevant way.

The C. DIFF QUIK CHEK COMPLETE test from TECHLAB, Inc. (Blacksburg, VA, USA), a part of the SSI Diagnostica Group (Hillerød, Denmark), is a rapid membrane enzyme immunoassay that detects both the C. difficile GDH antigen and toxins A and B in a single reaction well. This test combines the screening and toxin detection steps of the traditional two-step algorithm into one, enhancing workflow efficiency, reducing turnaround time, and offering cost savings compared to the PCR-first algorithm.

The ability to make rapid clinical decisions is crucial for the effective treatment of patients with C. difficile infections, making it essential to obtain both screening and toxin results quickly. The C. DIFF QUIK CHEK COMPLETE test delivers both GDH and toxin results in about 30 minutes, effectively distinguishing between active infections and colonization with a single test that is both cost-effective and clinically relevant. Furthermore, the C. DIFF QUIK CHEK COMPLETE test is the first combined GDH and toxin A/B test to receive certification under the European In Vitro Diagnostic Medical Device Regulation (IVDR), affirming its compliance with stringent quality and safety standards. This certification ensures the test’s reliability and effectiveness for clinical use across Europe and represents a significant step forward in SSI Diagnostica’s efforts to improve diagnostic tools for C. difficile infections.

“We are proud to achieve IVDR certification for our C. DIFF QUIK CHEK COMPLETE test,” said Christina Lindved, CEO of SSI Diagnostica Group, “This achievement underscores SSI Diagnostica’s commitment to delivering high-quality diagnostic tools that meet the stringent regulatory requirements and fulfill the needs of healthcare providers and patients worldwide.”

Related Links:
TECHLAB, Inc. 
SSI Diagnostica Group

Gold Member
C-Reactive Protein Reagent
CRP Ultra Wide Range Reagent Kit
Gold Member
Blood Gas Analyzer
GEM Premier 7000 with iQM3
New
Epstein-Barr Virus Test
ZEUS IFA Epstein-Barr Virus VCA IgG Test
New
hCG Urine Test
QuickVue hCG Urine Test

Print article

Channels

Pathology

view channel
Image: The unique AI tool predicts cancer prognoses and responses to treatment (Photo courtesy of Shutterstock)

AI Tool Combines Data from Medical Images with Text to Predict Cancer Prognoses

The integration of visual data (such as microscopic and X-ray images, CT and MRI scans) with textual information (like exam notes and communications between doctors of different specialties) is a crucial... Read more

Technology

view channel
Image: Human tear film protein sampling methods (Photo courtesy of Clinical Proteomics. 2024 Mar 13;21:23. doi: 10.1186/s12014-024-09475-8)

New Lens Method Analyzes Tears for Early Disease Detection

Bodily fluids, including tears and saliva, carry proteins that are released from different parts of the body. The presence of specific proteins in these biofluids can be a sign of health issues.... Read more

Industry

view channel
Image: The investment is in line with Danaher’s aim to accelerate the transition to precision medicine with AI-enabled diagnostics

Danaher Partners with Healthcare AI Company Innovaccer on Novel Digital and Diagnostic Solutions

Danaher Diagnostics LLC and Danaher Ventures LLC, two subsidiaries of Danaher Corporation (Washington, DC, USA), has formed an investment partnership with healthcare artificial intelligence (AI) company... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.